This article is part of our Skin Allergies resource center, covering all aspects of skin allergies diagnosis, treatment, and management.
What Atopic Dermatitis Is
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin condition characterized by intense itching, a disrupted skin barrier, and a Th2-dominant immune response. It is the most prevalent chronic skin disease in children and affects a substantial minority of adults. The term "atopic" refers to a genetic predisposition to develop allergic conditions — atopic dermatitis, allergic rhinitis, and asthma frequently coexist in the same individual, a pattern called the atopic march.
Eczema Terminology
Eczema is a general term for a group of inflammatory skin conditions, not a single diagnosis. Atopic dermatitis is the most common type and is specifically associated with immune dysregulation and a personal or family history of allergic disease. Other forms include contact dermatitis (a reaction to substances touching the skin), dyshidrotic eczema (blistering on the hands and feet), and nummular eczema (coin-shaped patches). This article addresses atopic dermatitis specifically. For comparison with psoriasis — a condition sometimes confused with eczema — see our eczema versus psoriasis guide.
Atopic Dermatitis — Clinical Statistics & Burden of Disease
31.6M
Americans affected by atopic dermatitis
(AAD 2024)
10–20%
of children worldwide have AD
(WAO 2024)
2–5%
of adults affected globally
(NIH 2024)
50%
of AD patients develop asthma (atopic march)
(ACAAI 2024)
3x
higher rate of sleep disruption vs non-atopic
(JACI 2023)
85%
of AD patients have onset before age 5
(AAD 2024)
Skin-Barrier Dysfunction
A defective skin barrier is central to atopic dermatitis pathophysiology. In healthy skin, tightly packed keratinocytes and structural proteins — including filaggrin — form a barrier that retains moisture and blocks environmental irritants and allergens. Many patients with AD carry mutations in the filaggrin gene (FLG), reducing the integrity of this barrier. The compromised barrier allows transepidermal water loss, making skin dry and prone to cracking, while simultaneously allowing environmental antigens, irritants, and microorganisms to penetrate more readily.
This dual failure — moisture loss and antigen penetration — drives the chronic inflammatory cycle. Allergens entering through the skin trigger a Th2-skewed immune response, which further impairs the barrier through cytokine-mediated effects. Effective long-term management requires repairing and maintaining the barrier as a primary goal, not just treating flares after they occur.
Common Symptoms
The hallmark symptom of atopic dermatitis is intense, persistent pruritus (itching). This is not a mild inconvenience — in moderate-to-severe AD it can be severe enough to disrupt sleep, affect concentration, and significantly impair quality of life. The itch-scratch cycle is a major contributor to skin damage: scratching damages the already-compromised barrier, introduces bacteria, and perpetuates inflammation.
The rash in AD appears in different forms depending on the stage and location. In acute flares it presents as red, weeping, or crusting patches. In chronic disease the skin becomes thickened, leathery, and hyperpigmented (lichenified). The distribution varies by age: infants typically develop patches on the face, scalp, and extensor surfaces; older children and adults tend to have involvement in the skin creases — the antecubital fossae (inner elbows), popliteal fossae (backs of knees), neck, and wrists.
Age-Related Patterns
Onset occurs before age five in approximately 85% of patients. Many children experience significant improvement or apparent resolution as they age, though a portion carry the condition into adulthood. Adult-onset atopic dermatitis is recognized and may present differently from the childhood form, sometimes with more diffuse involvement or a predominance of hand eczema. When AD is diagnosed in older adults without a personal or family atopic history, evaluation to rule out contact dermatitis or other mimics is warranted.
Flare Triggers
Identifying and managing individual flare triggers is a cornerstone of long-term AD control. Common triggers include: environmental allergens such as house dust mites, pet dander, and pollen; irritants including harsh soaps, detergents, wool, and synthetic fabrics; sweat and heat; stress (which activates inflammatory pathways); skin infections; and in some patients, certain foods. Triggers vary substantially between individuals, and not all patients share the same set. Our dedicated eczema flare trigger guide covers identification and avoidance strategies in detail.
Allergy Associations
Atopic dermatitis is closely associated with other allergic conditions. Patients with AD are at substantially elevated risk of developing allergic rhinitis and asthma — the atopic march — which typically follows in that developmental sequence. Inhalant allergen sensitization (to house dust mite, pet dander, pollens) is common in patients with AD and may worsen skin disease through airborne contact.
Food Allergy and Common Misconceptions
Food allergy can worsen atopic dermatitis in some patients, particularly young children with early-onset or severe disease. However, food allergy does not cause most cases of atopic dermatitis, and eliminating foods based on suspicion — without allergy testing — is frequently unhelpful and can cause nutritional harm. Broad food elimination diets should not be pursued without evaluation by a clinician. When food allergy is a genuine concern, evaluation through allergy testing — skin testing, specific IgE testing, and in some cases supervised oral food challenge — provides the evidence base for any dietary decisions.
Infection Warning Signs
The compromised skin barrier in atopic dermatitis creates significant susceptibility to skin infection. Bacterial superinfection with Staphylococcus aureus is extremely common — the organism colonizes the skin of most patients with AD and can trigger or dramatically worsen flares. Signs of bacterial infection include increasing redness, warmth, oozing, crusting with yellow or honey-colored discharge, and worsening despite usual treatment. Viral infections — particularly eczema herpeticum, caused by herpes simplex virus — can be serious and require prompt medical evaluation. Eczema herpeticum presents as painful clustered blisters or erosions spreading rapidly across previously eczematous skin and warrants urgent clinical assessment.
Diagnosis
Atopic dermatitis is a clinical diagnosis based on history and examination — there is no single definitive test. Diagnostic criteria include chronic or relapsing itchy skin, characteristic distribution, and personal or family history of atopic disease. Allergy testing (skin tests or specific IgE) is not required to diagnose AD itself, but may be useful when specific triggers are being evaluated or when food allergy is suspected. Patch testing may be helpful when contact dermatitis is a differential consideration. A dermatologist or allergist can confirm the diagnosis and assess severity using validated tools such as the EASI (Eczema Area and Severity Index) or IGA (Investigator Global Assessment).
Treatment Approaches
Moisturizers and Skin Care
Daily moisturization is the foundation of all AD management, regardless of severity. Applying a fragrance-free, dye-free emollient cream or ointment immediately after bathing — within three minutes, before the skin fully dries — traps moisture and partially compensates for barrier dysfunction. Ointments (petrolatum-based) provide superior occlusion but may not be practical for daytime use; creams are a reasonable alternative. This approach, sometimes called "soak and seal," should be maintained even when the skin appears clear.
Topical Treatments
Topical corticosteroids are the first-line anti-inflammatory treatment for active flares. They are used at the lowest potency effective for each body location — higher-potency formulations are appropriate for thickened skin on the trunk and extremities, while lower-potency preparations are used on the face, groin, and axillae. Topical calcineurin inhibitors (tacrolimus, pimecrolimus) provide steroid-sparing anti-inflammatory effect and are particularly useful for sensitive areas and long-term maintenance. Ruxolitinib cream (a JAK inhibitor) is FDA-approved for mild-to-moderate AD in patients aged 12 and older as a non-steroidal option.
Prescription and Advanced Treatment Categories
Patients with moderate-to-severe AD not adequately controlled with topicals may be candidates for systemic treatment. Dupilumab (Dupixent), a biologic that blocks IL-4 and IL-13 signaling, is FDA-approved for moderate-to-severe AD and has substantially changed the treatment landscape. Additional JAK inhibitors — abrocitinib and upadacitinib — are approved for moderate-to-severe AD in adults. Older systemic immunosuppressants (cyclosporine, methotrexate, azathioprine) remain in use where newer agents are not available or tolerated. The appropriate agent depends on severity, comorbidities, patient preference, and access.
| Therapy | Mechanism | When Used |
|---|---|---|
| Emollients (moisturizers) | Restores barrier function, prevents trans-epidermal water loss | Daily — foundation of all AD care |
| Topical corticosteroids (TCS) | Reduces flare inflammation via glucocorticoid receptor | Active flares — lowest effective potency per site |
| Topical calcineurin inhibitors | Inhibits T-cell activation — steroid-sparing | Maintenance, sensitive areas (face, folds) |
| Dupilumab (Dupixent) | Blocks IL-4/IL-13 signaling — biologic | Moderate-severe AD refractory to topicals |
| JAK inhibitors (oral) | Blocks JAK-STAT inflammatory pathway | Moderate-severe AD; adults with inadequate biologic response |
Sleep and Quality of Life
The impact of atopic dermatitis on sleep is substantial and underappreciated. Nocturnal pruritus — itching that worsens at night — disrupts sleep architecture, reduces total sleep duration, and contributes to fatigue, mood changes, and cognitive effects during the day. Children with AD show higher rates of behavioral problems and academic difficulties partly attributable to chronic sleep disruption. For caregivers, nighttime management of a child's AD adds its own burden. Treatment that achieves good daytime disease control typically improves nighttime symptoms, but addressing sleep as a specific outcome is a legitimate therapeutic goal rather than a secondary concern.
Children and Atopic Dermatitis
AD is predominantly a pediatric condition, and managing it in children involves additional considerations. Parents and caregivers must apply moisturizers and topical treatments consistently, manage the emotional toll of a visibly uncomfortable child, navigate school and social settings, and make informed decisions about trigger avoidance. Children with AD are at risk of the atopic march — developing allergic rhinitis and asthma — making early, effective management of the skin disease a potential influence on the subsequent allergic trajectory.
Atopic Dermatitis Daily Care Protocol
- Moisturize within 3 minutes of bathing (soak and seal) — minimum twice daily, including clear-skin periods
- Use fragrance-free, dye-free emollient cream or ointment — avoid standard lotions (high water content, less effective)
- Bathe in lukewarm water for 5–10 minutes — hot water worsens pruritus and barrier dysfunction
- Apply topical corticosteroid to active flare areas as directed — do not apply to unaffected skin
- Identify and reduce personal triggers: house dust mite, certain fabrics, sweat, fragrances, stress
- Use fragrance-free, dye-free laundry detergent; double-rinse clothing and bedding
- Watch for signs of bacterial superinfection: increased redness, oozing, yellow crust — seek care promptly
- Keep nails trimmed short to limit skin damage during nighttime scratching
When to See a Clinician
Seek evaluation by a dermatologist or allergist when: AD does not improve with consistent first-line moisturizer and topical corticosteroid use; symptoms significantly disrupt sleep or daily function; signs of skin infection develop; moderate-to-severe disease in a child raises concerns about growth or nutrition; or prescription advanced therapy is being considered. An allergist can evaluate for relevant sensitizations; a dermatologist can assess severity and manage topical and systemic treatment. Many patients with moderate-to-severe disease benefit from co-management between the two specialties.